Try our Advanced Search for more refined results

Expert Analysis

What Really Doomed Kidney Test Patents In Fed. Circ. Ruling

By Javier Mixco, Cory Smith and George Chen ( December 16, 2022, 5:08 PM EST) -- In the CareDx Inc. v. Natera Inc. decision, the U.S. Court of Appeals for the Federal Circuit added to the long line of patent eligibility rulings — holding the patents that Stanford University and its exclusive licensee CareDx Inc. asserted against Natera Inc. and Eurofins Viracor Inc. were patent-ineligible because they attempted to claim the use of natural phenomena with well-known techniques to diagnose organ transplant rejection.[1] ...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!